Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Webinar Archive – MRD: What Should it Mean to Me?

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

Recorded August 14, 2020.


Patty Koffman
Co-founder and Communications Director
CLL Society


Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd
Executive Vice President and Chief Medical Officer
CLL Society


Anthony Mato, MD, MSCEAnthony Mato, MD, MSCE
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, NY

My primary focus is providing excellent care to people with chronic lymphocytic leukemia (CLL). At MSK, I serve as Director of the CLL Program. I oversee a team of experts who are entirely dedicated to all aspects of diagnosing and treating CLL. Our combined expertise allows us to develop the best treatment plans tailored to each patient’s unique situation. We can safely administer current therapies and also provide access to the newest treatments through clinical trials. Our mission is to provide people with CLL with state-of-the-art monitoring and treatments through clinical research and expertise.


MRD (minimal or measurable residual disease) is important to understand, not just in clinical trials, but increasingly in guiding real world CLL decisions you may need to make with your doctors. Join Dr. Anthony Mato as he discusses testing and research on MRD and its growing role in CLL management along with Dr. Brian Koffman.

This program was made possible by grant support by Adaptive Biotechnologies, Bristol Meyers Squibb, and Genentech.